ATE451917T1 - Pharmazeutische zubereitung enthaltend einen nmda rezeptor agonisten für die behandlung von bewegungsstörungen - Google Patents

Pharmazeutische zubereitung enthaltend einen nmda rezeptor agonisten für die behandlung von bewegungsstörungen

Info

Publication number
ATE451917T1
ATE451917T1 AT03258147T AT03258147T ATE451917T1 AT E451917 T1 ATE451917 T1 AT E451917T1 AT 03258147 T AT03258147 T AT 03258147T AT 03258147 T AT03258147 T AT 03258147T AT E451917 T1 ATE451917 T1 AT E451917T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical preparation
receptor agonist
preparation containing
nmda receptor
Prior art date
Application number
AT03258147T
Other languages
English (en)
Inventor
Uriel Heresco-Levy
Original Assignee
Sarah Herzog Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarah Herzog Memorial Hospital filed Critical Sarah Herzog Memorial Hospital
Application granted granted Critical
Publication of ATE451917T1 publication Critical patent/ATE451917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03258147T 2003-02-06 2003-12-24 Pharmazeutische zubereitung enthaltend einen nmda rezeptor agonisten für die behandlung von bewegungsstörungen ATE451917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL154318A IL154318A (en) 2003-02-06 2003-02-06 Pharmaceutical compositions for the treatment of movement disorders

Publications (1)

Publication Number Publication Date
ATE451917T1 true ATE451917T1 (de) 2010-01-15

Family

ID=30011985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03258147T ATE451917T1 (de) 2003-02-06 2003-12-24 Pharmazeutische zubereitung enthaltend einen nmda rezeptor agonisten für die behandlung von bewegungsstörungen

Country Status (7)

Country Link
US (3) US8629105B2 (de)
EP (1) EP1444979B1 (de)
AT (1) ATE451917T1 (de)
CA (1) CA2454337C (de)
DE (1) DE60330542D1 (de)
ES (1) ES2336091T3 (de)
IL (1) IL154318A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519485T1 (de) 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
JP2006265177A (ja) * 2005-03-24 2006-10-05 Taiyo Kagaku Co Ltd チック障害改善用組成物
US20100048653A1 (en) * 2005-07-14 2010-02-25 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2010053976A2 (en) * 2008-11-04 2010-05-14 Mclean Hospital Corporation Drug-enhanced neurofeedback
NZ598668A (en) 2009-09-01 2014-07-25 Lz Therapeutics Inc Methods for extraction and purification of gangliosides
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
US10583138B2 (en) * 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX2014008797A (es) 2012-01-20 2014-10-30 Garnet Biotherapeutics Inc Metodos para la produccion gangliosidos.
US9040581B1 (en) * 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
CA2913454C (en) 2013-05-28 2021-09-07 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-induced glutamatergic receptor dysfunction methods and treatments
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
US10639135B2 (en) 2017-11-07 2020-05-05 International Business Machines Corporation Temporal mandible data capture analysis and recommendation
CA3082834A1 (en) * 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
US11484519B2 (en) 2019-03-07 2022-11-01 Florida State University Research Foundation, Inc. D-serine inhibit neuroinflammation due to a brain injury
US20220313640A1 (en) * 2019-05-29 2022-10-06 Dario Doller Deuterated analogs of d-serine and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795738A (en) * 1972-12-26 1974-03-05 Abbott Lab Use of l-propyl l-leucyl glycine amide to treat parkinson's disease
US3851055A (en) * 1973-03-01 1974-11-26 Abbott Lab Method of treating tardive dyskinesia using l-prolyl l-leucyl glycine amide
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
JP4313435B2 (ja) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
JP2002528507A (ja) * 1998-10-30 2002-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 神経疾患および病態心理学的疾患の治療および予防用の組成物
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease

Also Published As

Publication number Publication date
IL154318A (en) 2010-05-31
US20140121254A1 (en) 2014-05-01
CA2454337A1 (en) 2004-08-06
US20040157926A1 (en) 2004-08-12
US9029410B2 (en) 2015-05-12
US8629105B2 (en) 2014-01-14
EP1444979B1 (de) 2009-12-16
CA2454337C (en) 2013-02-05
IL154318A0 (en) 2003-09-17
ES2336091T3 (es) 2010-04-08
US9271966B2 (en) 2016-03-01
DE60330542D1 (de) 2010-01-28
US20140187597A1 (en) 2014-07-03
EP1444979A1 (de) 2004-08-11

Similar Documents

Publication Publication Date Title
DE60330542D1 (de) Pharmazeutische Zubereitung enthaltend einen NMDA Rezeptor Agonisten für die Behandlung von Bewegungsstörungen
PL1978912T3 (pl) Opakowanie dla produktów medycznych i podobnych
EP2982696A3 (de) Behandlung von akuter lymphoblastenleukämie
MXPA03007712A (es) Sales farmaceuticas.
DE602004010493D1 (de) Kaugummi in der form von mehrschichttabletten
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
UA108594C2 (uk) Одинична дозована фармацевтична форма
ZA200410109B (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability.
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
MEP55308A (en) New pharmaceutical compositions containing flibanserin polymorph a
ATE488225T1 (de) Kaubare, lutschbare und verschluckbare tablette mit einer calciumhaltigen verbindung als wirkstoff
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
MXPA02011465A (es) Sal de creatina que tiene eficacia terapeutica y nutricional mejorada y composiciones que contienen la misma.
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
ITRM20030485A1 (it) Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
ATE338567T1 (de) Pharmazeutische zubereitungen, wirkstoffe enthaltend, die sich für unerlaubte verabreichung anbieten
WO2007046123A3 (en) Composition containing vitamins k and d as well as taurine for the preventio and treatment of osteoporosis
NO20044519L (no) Hyperforinderivater, anvendelse derav samt formuleringer som inneholder dem
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
BR0300548A (pt) Composição, medicamento, medicamento para a profilaxia ou terapia da pancreatite, suplemento alimentar, alimento de cuidado da saúde, ração, e, método para produzir a composição
TW200718416A (en) Drug composition for memory reduction and uses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties